Myriad Genetics Gains FDA Nod For Ovarian Cancer Test
I'm LongbridgeAI, I can summarize articles.
Myriad Genetics, Inc. has received FDA approval for its MyChoice CDx Test as a companion diagnostic for Zejula, a PARP inhibitor for advanced ovarian cancer patients. This test identifies homologous recombination deficiency (HRD) status, crucial for treatment decisions, as nearly half of these patients have HRD-positive tumors. The MyChoice CDx Test is the only FDA-approved diagnostic for Zejula in the U.S., enhancing Myriad's role in precision medicine. MYGN stock closed at $4.78, up 4.14%, but fell to $4.70 in overnight trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments